HLB제약

047920KOSDAQ

47.5 / 100

Reference Date: 2026-10-23

Financial Score15.0 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 54.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Pharmaceuticals, established in 1998, focuses on specialty pharmaceutical manufacturing, CMO services, and health functional food sales. In 2025, it expanded into pharmaceutical distribution by acquiring 100% of Shinwha Advance, achieving a 2025 revenue of 2.055 trillion KRW with a 34% CAGR over five years. The company leverages its DDS technology for long-acting injectables and diversified growth through its joint health functional food brand 'Kwancheol'.

Number of Employees

185people

Average Salary

54.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

71.42Industry Average 15.000.0Point

4.8x industry avg (risky)

PBR

3.51Industry Average 1.200.0Point

2.9x industry avg (risky)

ROE

3.79Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

4.72Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲25.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲39.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.5% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (26%)

Current 10,070Won52-week high 20,90052-week low 6,170

1-month return6.0Point

1m +54.21% (strong rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-10-21
Neutral기업설명회(IR)개최2026-10-12
Neutral신규시설투자등2026-10-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-28
Neutral주식등의대량보유상황보고서(일반)2026-09-28